TICKERNERD
Menu
MANEHealthcare · Biotechnology

MANE Stock Forecast: Veradermics, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$99
+0.85% on the day

The 7 Wall Street analysts covering Veradermics, Inc. hold a median 12-month price target of $167 — +68.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 2 of 100 as at 12 Sept 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$4.1B
Ticker Nerd rank
2 / 100
Median analyst target
$167
Analysts covering
7
Revenue$0.0
Operating income−$29.6M
Net income−$23.5M
Free cash flow−$14.5M
Quarterly, 6 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+1.2%
1M
−9.2%
From high
−23.7%
From low
+167.3%
$37
$130
Range since 4 Feb 2026, adjusted closes · the dot is the last close
Ticker Nerd rank

MANE stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Veradermics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
2 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
52
Size
26
Momentum
18
Issuance
15
Value
15
Growth
8
Accruals
8
Quality
4
Volatility
3

Revisions (52): Analysts have, on balance, been raising their forecasts.

Volatility (3): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

MANE stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on MANE, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, since 4 Feb 2026Adjusted close, US dollars
$50$100$150$200Apr 26Jul 26MANEHigh $182Median $167Low $135

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says7 analysts
7 Buy0 Hold0 Sell
Low $135Median $167High $182

The green dot is the last close — the median target sits +68.7% from it.

Recent analyst actionsNewest first

Of the 13 most recent actions, 3 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
16 July 2026CitigroupMaintainsBuy$135 → $160
15 July 2026B. Riley SecuritiesInitiatesBuy$170
15 July 2026NeedhamMaintainsBuy$136 → $164
7 July 2026JefferiesMaintainsBuy—
7 July 2026JefferiesMaintainsBuy$138 → $182
16 June 2026LifeSci CapitalInitiatesOutperform—
2 June 2026NeedhamInitiatesBuy—
18 May 2026CitigroupMaintainsBuy—
22 Apr 2026Leerink PartnersMaintainsOutperform—
2 Mar 2026Cantor FitzgeraldInitiatesOverweight—
2 Mar 2026CitigroupInitiatesBuy—
2 Mar 2026JefferiesInitiatesBuy—
2 Mar 2026Leerink PartnersInitiatesOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. MANE appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

MANE vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

MANE vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200250300350Apr 26Jul 26MANES&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

MANE analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Veradermics, Inc. (MANE) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−41.6×

Cheaper than 98% of US stocks

Price / sales
—
Price / book
5.1×

Cheaper than 20% of US stocks

EV / EBITDA
−47.4×

Cheaper than 94% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
68.9%

Higher than 95% of US stocks

Return on assets
−54.6%

Higher than 7% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Veradermics, Inc. (MANE) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Veradermics, Inc. has a market value of $4.1B and an enterprise value of $3.3B.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$92.7M.

  • Free cash flow in the twelve months to 30 June 2026: −$78.3M.

  • Shares outstanding: 41.8M.

  • Trailing P/E: −41.6×; forward P/E: −36.8× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Veradermics, Inc. employs 37 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Sept 2026

Data provided by Twelve Data

Peers

MANE vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
MANEVeradermics, Inc.$4.1B
2
CELCCelcuity, Inc.$4.1B
27
RLAYRelay Therapeutics, Inc.$4.0B
71
ELVNEnliven Therapeutics, Inc.$3.9B
68
TNGXTango Therapeutics, Inc.$3.9B
41
IOVAIovance Biotherapeutics, Inc.$3.8B
90
PBLSParabilis Medicines, Inc.$4.4B
0

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Veradermics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest MANE news & analysis

Veradermics, Incorporated (MANE) Presents at Citigroup's Biopharma Back to School Summit 2026 Prepared Remarks Transcript

Seeking Alpha · 10 Sept 2026neutral

Veradermics, Incorporated presented prepared remarks at Citigroup's Biopharma Back to School Summit 2026, as covered by Seeking Alpha. The transcript of this presentation was published for investors.

Why it matters — MANE watchers would care because the company presented to the investment community at a major biopharma conference, providing an opportunity to hear its prepared remarks.

Veradermics to Present at Upcoming September Investor Conferences

Business Wire · 3 Sept 2026neutral

Veradermics, Incorporated (NYSE: MANE), a late-stage biopharmaceutical company focused on pattern hair loss therapeutics, announced that company management will present and participate in investor meetings at the Wells Fargo 21st Annual Healthcare Conference in Boston on September 8, 2026, and Citi's 2026 Biopharma Back to School Conference in September.

Why it matters — MANE watchers would care because these investor conference appearances provide opportunities for company management to present its pipeline and engage with the investment community.

Veradermics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress

Business Wire · 11 Aug 2026positive

Veradermics reported financial results for the second quarter ended June 30, 2026, and highlighted recent corporate and clinical progress, including significant advancements in the development of VDPHL01 for female pattern hair loss.

Why it matters — The update signals forward momentum in the company's lead pipeline candidate for pattern hair loss, a key value driver for MANE.

FAQ

Frequently asked questions about MANE stock

What is the MANE stock price forecast for 2026-2027?

The 7 Wall Street analysts covering Veradermics, Inc. have a median 12-month price target of $167, with estimates ranging from $135 to $182. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is MANE stock a buy right now?

Of the 7 analysts covering Veradermics, Inc., 7 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Veradermics, Inc. 2 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank MANE?

As at 12 Sept 2026, Veradermics, Inc. ranks 2 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (52 of 100).

Will MANE stock go up?

No one can know that. What the data says: the median 12-month target from 7 analysts implies +68.7% from the last close, and Ticker Nerd's factor model ranks Veradermics, Inc. 2 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the MANE stock forecast for 2030?

No analyst covering Veradermics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MANE are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $135 to $182 over the next 12 months.

What does Veradermics, Inc. do?

Veradermics, Incorporated is a late clinical-stage biopharmaceutical company focused on developing dermatology and aesthetic treatments. Its current pipeline centers on therapies for pattern hair loss, including VDPHL01, an oral, non-hormonal, extended-release minoxidil formulation designed for men and women.

What is the latest news on MANE?

The most recent item we track (Seeking Alpha, 10 Sept 2026): "Veradermics, Incorporated (MANE) Presents at Citigroup's Biopharma Back to School Summit 2026 Prepared Remarks Transcript". Veradermics, Incorporated presented prepared remarks at Citigroup's Biopharma Back to School Summit 2026, as covered by Seeking Alpha. The transcript of this presentation was published for investors.

Company

About Veradermics, Inc.

Veradermics, Incorporated is a late clinical-stage biopharmaceutical company focused on developing dermatology and aesthetic treatments. Its current pipeline centers on therapies for pattern hair loss, including VDPHL01, an oral, non-hormonal, extended-release minoxidil formulation designed for men and women. The company is also developing additional product candidates and delivery technologies for common skin and hair-related conditions such as alopecia areata, common warts, molluscum contagiosum, and atopic dermatitis. Veradermics serves healthcare providers, dermatology clinicians, and medical researchers involved in treating adult and pediatric patients. Headquartered in New Haven, Connecticut, and incorporated in 2019, Veradermics operates as a focused biotech company addressing prevalent dermatologic conditions through targeted therapeutic development.

CEO Dr. Reid Waldman M.D. · 37 employees · United States · https://www.veradermics.com